Main content

    Kidney and Pancreas Transplant Program

    Kidney and Pancreas Transplant ProgramOpens new window | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression
    Description: The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-36 months after kidney transplant
    Investigator: V. Ram Peddi, MD
    Eligibility: Subject between 18 and 75 years old who are recipients of a renal allograft from a living donor or a deceased donor between 6-36 months prior to enrollment
    Status: Active and open to enrollment
    Contact: Serena Lai, 415-600-1744, Email: LaiS@cpmcri.org about Study BMS 116

    Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
    Description: The purpose of this study is to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study will also evaluate the safety of ASP0113 in this patient population
    Investigator: V. Ram Peddi, MD
    Eligibility: Subjects 18 years and older who ae CMV negative and having received a CMV seropositive kidney (living or deceased)
    Status: Active and open to enrollment
    Contact: Lisa Takemori, 415-600-1627, Email: TakemoriL@cpmcri.org about Study Astellas 0113

    Title: A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation
    Description: This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients
    Investigator: V. Ram Peddi, MD
    Eligibility: Subjects 18 years and older who are a recipient of a kidney with a cold ischemia time < 30 hours
    Status: Active and open to enrollment
    Contact: Lisa Takemori, 415-600-1627, Email: TakemoriL@cpmcri.org about Study RAD 2433

    Title: A Multi-Center Trial to Procure EDTA Blood Samples From Everolimus-Treated Patients For TDM Assay Validation and Proficiency Testing
    Description: The goal of this trial is to procure blood samples from Everolimus-treated patients of gender, age, ethnic and clinical diversity
    Investigator: Lawrence H. Lu, MD
    Eligibility: Kidney transplant recipients taking Everolimus
    Status: Active and open to enrollment
    Contact: Serena Lai, 415-600-1744, Email: LaiS@cpmcri.org about Study RAD Assay

    Title: A Phase 2a, Randomized, Open-label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
    Description: A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
    Investigator: V. Ram Peddi, MD
    Eligibility: Subjects 18 y/o and older who are a recipient of a de novo kidney from a living or deceased donor
    Status: Active but closed to enrollment
    Contact: Serena Lai, 415-600-1744, Email: LaiS@cpmcri.org about Study Astellas 0108

    • updated September 2014